Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008–2016

Autor: Penina Haber, Muhammad Amin, Carmen Ng, Eric Weintraub, Michael M. McNeil

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 14, Iss 11, Pp 2755-2759 (2018)

A 2018 manufacturer post-licensure safety study identified a possible association between Rotarix (RV1) rotavirus vaccine and lower respiratory tract infections (LRTI) in infants within 0–6 days following receipt of RV1 dose 1. We reviewed reports

Externí odkaz: https://doaj.org/article/360e882f06b1453583d2bb8b11109892

Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017

Autor: Graça M. Dores, Paige Marquez, Carmen Ng, Maria Cano, Penina Haber, Silvia Perez-Vilar, John R. Su

Publikováno v: Vaccine

BACKGROUND: Since the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced in the United St

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e06239bc37ebf0501a643b4d4f1118a
https://doi.org/10.1016/j.vaccine.2019.12.028

Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices

Autor: Aaron M. Harris, John W. Ward, Noele P. Nelson, Claudia Vellozzi, Arthur Reingold, Penina Haber, Sarah Schillie

Publikováno v: MMWR Recommendations and Reports
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, vol 67, iss 1

Summary Hepatitis B virus (HBV) is transmitted via blood or sexual contact. Persons with chronic HBV infection are at increased risk for cirrhosis and liver cancer and require medical care. This report updates and summarizes previously published reco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7928363d31da2ab2502fa0beec2c7e
https://doi.org/10.15585/mmwr.rr6701a1

Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention

Autor: Pedro L. Moro, Michael M. McNeil, Penina Haber

Publikováno v: Expert review of vaccines. 18(10)

Introduction: Vaccination is one of the most successful and cost-effective public health interventions. Although vaccines undergo extensive safety and efficacy evaluations prior to licensure, vaccine safety assessment post-licensure is essential for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dafc0c29ee9f8581950c6d172c605ccb
https://pubmed.ncbi.nlm.nih.gov/31580725

Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018

Autor: Paige Lewis, Pedro L. Moro, Graça M. Dores, Carmen Ng, Penina Haber, Maria Cano

Publikováno v: Vaccine. 37(11)

BACKGROUND Trivalent adjuvanted influenza vaccine (aIIV3; Fluad®) was approved in the United States (U.S.) in 2015 for adults aged ≥65 years and has been in use since the 2016-17 influenza season. METHODS We analyzed U.S. reports for aIIV3 submitt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb36f7b45615e77796036b797e1e6a54
https://pubmed.ncbi.nlm.nih.gov/30739795